tradingkey.logo

Nexalin Technology Inc

NXL

0.935USD

+0.145+18.42%
終値 09/19, 16:00ET15分遅れの株価
16.28M時価総額
損失額直近12ヶ月PER

Nexalin Technology Inc

0.935

+0.145+18.42%
詳細情報 Nexalin Technology Inc 企業名
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
企業情報
企業コードNXL
会社名Nexalin Technology Inc
上場日Sep 16, 2022
最高経営責任者「CEO」Mr. Mark White
従業員数6
証券種類Ordinary Share
決算期末Sep 16
本社所在地1776 Yorktown
都市HOUSTON
証券取引所NASDAQ Capital Market Consolidated
United States of America
郵便番号77056
電話番号18322600222
ウェブサイトhttps://nexalin.com
企業コードNXL
上場日Sep 16, 2022
最高経営責任者「CEO」Mr. Mark White
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
149.29K
--
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+25.00%
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
149.29K
--
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+25.00%
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Equipment
19.81K
48.30%
Licensing Fee
17.31K
42.21%
Other
3.89K
9.48%
Device Sales
0.00
0.00%
地域別USD
会社名
収益
比率
International Sales
20.57K
50.16%
U.S. Sales
20.44K
49.84%
事業別
地域別
事業別USD
会社名
収益
比率
Equipment
19.81K
48.30%
Licensing Fee
17.31K
42.21%
Other
3.89K
9.48%
Device Sales
0.00
0.00%
株主
更新時刻: Sun, Aug 17
更新時刻: Sun, Aug 17
株主統計
種類
株主統計
株主統計
比率
Elson (Marilyn)
8.81%
MYDA Advisors LLC
4.59%
Hu (Benjamin)
1.96%
White (Mark)
1.77%
The Vanguard Group, Inc.
0.92%
他の
81.94%
株主統計
株主統計
比率
Elson (Marilyn)
8.81%
MYDA Advisors LLC
4.59%
Hu (Benjamin)
1.96%
White (Mark)
1.77%
The Vanguard Group, Inc.
0.92%
他の
81.94%
種類
株主統計
比率
Individual Investor
14.34%
Hedge Fund
5.18%
Investment Advisor
1.22%
Investment Advisor/Hedge Fund
0.99%
Venture Capital
0.13%
他の
78.14%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
41
2.88M
16.54%
-349.86K
2025Q1
40
2.89M
20.99%
-330.73K
2024Q4
39
2.84M
22.05%
+425.03K
2024Q3
30
2.89M
23.47%
+756.88K
2024Q2
27
1.82M
24.31%
-214.81K
2024Q1
20
1.77M
23.82%
-386.75K
2023Q4
19
1.75M
24.04%
-404.23K
2023Q3
19
1.79M
24.48%
+126.81K
2023Q2
18
1.72M
23.56%
+25.67K
2023Q1
20
1.79M
24.55%
+114.75K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Elson (Marilyn)
1.54M
8.81%
--
--
Jun 04, 2025
Hu (Benjamin)
340.64K
1.96%
--
--
Jun 04, 2025
White (Mark)
309.13K
1.77%
--
--
Jun 04, 2025
The Vanguard Group, Inc.
159.88K
0.92%
+34.42K
+27.43%
Mar 31, 2025
Owens (David)
149.29K
0.86%
--
--
Jun 04, 2025
Geode Capital Management, L.L.C.
114.07K
0.65%
+6.83K
+6.37%
Mar 31, 2025
Kazden (Alan)
83.13K
0.48%
--
--
Jun 04, 2025
Bernhard (Leslie)
49.84K
0.29%
--
--
Jun 04, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
KeyAI